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Purpose: To formulate and evaluate glibenclamide (GB)-loaded poly(lactic-co-glycolic) acid (PLGA) 
nanoparticles (NPs) for controlled release. 
Methods: GB-loaded PLGA NPs were prepared by solvent evaporation technique using 
methanol/dichloromethane (2:1) and characterized by transmission electron microscopy (TEM), and 
differential scanning calorimetry (DSC). The effect of stirring speed (250, 1000, 1500 and 2500 rpm) and 
drug: polymer ratio (1:1, 1: 2, 1:3 and 2:1) on particle size, size distribution, zeta potential, drug loading, 
encapsulation efficiency and drug release was also studied. 
Results: Stable NPs were successfully prepared without any incompatibility, as indicated by TEM and 
DSC studies, respectively. As polymer and drug concentrations, and stirring speed increased, particle 
size, drug loading and encapsulation efficiency also increased. Increase in polymer concentration 
sustained drug release but reverse was obtained as drug concentration increased. 
Conclusion: Controlled release biodegradable glibenclamide NPs can be efficiently prepared by 
emulsification solvent evaporation method suitably modulating processing variables. 
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INTRODUCTION 
 
Nanoparticles (NPs) are one of the 
multiparticulate delivery systems used for 
prolonged and/or controlled drug delivery, 
improved bioavailability, stability, and 
targeted drug delivery to specific sites [1-4]. 
NPs can also offer advantages such as 
limiting fluctuation within a therapeutic range, 
reducing side effects, decreasing dosing 
frequency, and improving patient compliance. 
 
Poly (lactic-co-glycolic) acid (PLGA) is a 
biodegradable polymer that has been used 
extensively for preparation of controlled 
release nanoparticulate drug delivery 
systems. The release kinetics of PLGA and 
other biodegradable polymers are controlled 
by diffusion, erosion or combinations thereof, 
and are dependent on the polymer molecular 
weight, copolymer ratio and crystallinity. 
 
Glibenclamide (GB) is a second-generation 
sulfonylurea oral hypoglycaemic agent used 
in the treatment of non-insulin dependent 
diabetes mellitus. It is administered in low 
doses (5 mg) and its active metabolites have 
a significant hypoglycemic effect. However, 
glibenclamide’s  low bioavailability has been 
attributed to its poor dissolution properties. 
Nanoparticle formulation can be used to 
formulate poorly soluble drugs to enhance 
bioavailability using an erosion-based 
biodegradable polymer such as PLGA [5-12]. 
 
 The present investigation aims to formulate 
and characterize PLGA controlled release 
nanoparticles containing GB by emulsification 





Poly (lactic-co-glycolic) acid (PLGA, 
copolymer ratio, 50:50, viscosity, 0.41 dL/g) 
was purchased from Birmingham Polymers 
Inc. (Birmingham, USA) while glibenclamide 
(GB) was received as a gift from Alembic 
Pharma, India. All other chemicals used were 
of analytical grade and obtained from E. 
Merck (India). 
 
Methods of Preparation of GB-loaded NPs 
 
GB-loaded PLGA nanoparticles (NPs) were 
prepared by emulsification solvent 
evaporation method. An attempt was made to 
optimize the nanoparticle formulation using 
various formulation parameters including 
varying drug/polymer ratio organic solvent  
(methanol/dichloromethane) ratio, stirring 
speed (250 – 2500 rpm) and surfactant ratio 
(PVA/polysorbate-80) in a fixed concentration 
(0.5 %w/v), using a modified emulsification 
solvent evaporation technique. PLGA and GB 
were dissolved in 25 ml of solvent mixture 
containing methanol to dichloromethane in a 
ratio 2:1, using a vortex shaker to form a 
homogeneous solution of drug and polymer. 
This homogeneous solution was added 
slowly to 120 ml of aqueous surfactant 
solution containing 0.5 % w/v polyvinyl 
alcohol and polysorbate-80, and 
homogenised using a high pressure 
homogenizer (Ika, Japan) to obtain an 
emulsion [13-15]. The emulsion formed was 
stirred with a laboratory magnetic stirrer 
(Remi, India) for 5 h at 25 ºC followed by 
centrifugation (Remi, India) for 22 min. The 
supernatant was discharged and the pellets 
obtained were washed using the same 
volume of distilled water as the supernatant 
and then centrifuged for 6 min. Washing was 
repeated three times and the resulting NPs 
were freeze-dried (Lyphlock, Labconco). 
 
Determination of drug incorporation 
efficiency 
 
The freeze-dried NPs (10 g) were dissolved 
in dichloromethane (50ml), a common solvent 
for both drug and polymer. The amount of 
drug in the solution was determined using 
Perkin-Elmer ultraviolet spectrophotometer at 
243.5 nm. Drug content (%w/w) and drug 
entrapment (%) were calculated using Eqs 1 
and 2, respectively. 
 
 % Drug content = (M/Mr)100  .................. (1) 
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where M is the mass of drug in the NPs and 
Mr the mass of NPs recovered.   
 
% Drug entrapment = (D/Df)100 .............. (2) 
 
where D = amount of drug in the nanoparti-
cles and Df = total amount of drug used for 
the preparation of the nanoparticles. 
 
Particle size analysis and zeta potential 
measurement 
 
Freeze-dried NPs were reconstituted in 
distilled water. The size of the NPs was 
determined by Zetasizer (Nano ZS, Malvern 
Instruments, Malvern, UK) based on dynamic 
light scattering technique. The polydispersity 
index (PI), which is a dimensionless number 
indicating the width of the size distribution, 
was also measured. The mean particle size 
of the formulation was determined by 
photocorrelation spectroscopy with a zeta 
master (Malvern Instruments, UK) equipped 
with the Malvern PCS software. Each sample 
was diluted with phosphate buffer (pH 7.4) 
and the surface charge (zeta potential) of the 
NPs determined by measuring their 
electrophoretic mobility of the NPs by the 
zeta sizer (Malvern Instruments, UK).  
 
Differential scanning calorimetric (DSC) 
studies 
 
The physical state of glibenclamide 
encapsulated in NPs was characterized by 
differential scanning calorimetry (DSC, 
Shimadzu, DSC-50, Japan). Each sample 
containing the drug, equivalent to 10 mg, was 
sealed separately in a standard aluminium 
pan, the samples were purged with nitrogen 
gas at a flow rate of 10 ml/min, and heated at 
10 °C/min from 0 to 350 °C 
 
Transmission electron microscopic 
studies 
 
NPs were also evaluated for size with a 
transmission electron microscope (Philips/FEI 
Inc, Barcliff, Manor, NY, USA). For this 
purpose, a sample of NPs was suspended in 
water (0.5 mg/ml) and sonicated for 30 s. 
One drop of this suspension was placed over 
a carbon-coated copper TEM grid (150 mesh, 
Ted Pella Inc., Rodding, CA) and negatively 
stained with 1 % uranyl acetate for 10 min 
and then allowed to dry. Images were 
visualized at 120 kV under the microscope.  
 
In vitro drug release studies 
 
The in vitro release of GB-loaded NPs were 
performed using USP type II dissolution test 
apparatus (Electrolab, India) in 900 ml of 
medium ( 0.1M hydrochloric acid) for the first 
2 h and then in phosphate buffer (pH 7.5) 
from 3 - 72 h at 37 ± 0.5 °C and stirring rate 
of 100 rpm. Samples (5 ml) were collected 
periodically and replaced with equal volume 
of fresh dissolution medium on each 
occasion. After filtration through Whatman 
Grade No. 41 Quantitative Filter Paper (pore 
size 25 µm), the concentration of GB was 
determined spectrophotometrically at 243.5 
nm on UV-Visible spectrophotometer (Jasco 
V530, Japan). In vitro release profile was 
analyzed by various kinetic models (zero 
order, first order and Higuchi) in order to 





The results are expressed as mean ± 
standard deviation (SD, n = 3). The data 
were statistically analyzed by one-way 
analysis of variance using Graph Pad Instat®, 
version 3.05 (USA), and significant difference 




Entrapment efficiency, drug content, 
particle size and characteristics 
 
The entrapment efficiency (EE), drug content 
(DC) and particle size (PS) of the 
formulations (with their codes) is given in 
Table 1. As the concentration of polymer 
increased, entrapment efficiency and particle 
size also increased. Lower particle size were 
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observed when stirring speed was increased. 
TEM photographs (Fig 1) indicate that NPs 
were spherical in shape and in the nanosize 
range with discrete spherical outline. DSC 
thermograms of native PLGA, GB and GB-
loaded NPs showed the characteristic peaks 
of the respective compounds, as shown in 
Figure 2. An endothermic peak of PLGA 
occurred at around 48 ºC due to glass 
transition (Tg). The peak of PLGA was 
slightly shifted to 46.5 ºC   in drug-loaded 
NPs compared to that of native PLGA. The 
endothermic peak of native GB occurred at 
172.8 ºC.  In formulation F2, no similar peaks 
were observed, indicating that the drug was 
molecularly dispersed in the polymer matrix.  
 
In vitro release profile and kinetics of the GB 
NPs are shown in Figure 3 and Table 2, 
respectively. As polymer concentration 
increased, drug release decreased. Also, 
when the drug concentration of the NPs was 
increased as in case of formulation F2 (drug: 
polymer ratio 1:2) as compared to formulation 
F1 (drug: polymer ratio 1:1), drug release 
increased.  In order to determine the release 
pattern of GB from prepared NPs, various in 
vitro release kinetic models such as zero 
order, Higuchi and first order were analysed. 
In all formulations, the highest regression 
coefficient was observed using zero order 
model (Table 2).  
 
Table 1: Effect of drug/polymer ratio (D:P), stirring speed (SP), entrapment efficiency (EE), drug content 












F1 1:1 2500 46.32 ± 
2.14* 
11.21 ± 2.43* 532 ± 11.29* 
F2 1:2 2500 54.24 ± 
3.15 
26.52 ± 3.16 562 ± 5.28 
F3 1:3 2500 62.63 ± 
1.87* 
28.51 ± 2.29* 812 ± 
14.72** 
F4 2:1 2500 90.52 ± 
4.52** 
36.73 ± 3.16* 1453 ± 
13.26** 
F5 1:2 250 33.21 
±3.12** 
10.28 ± 1.13* 1081 ± 
23.26** 
F6 1:2 1000 42.24 ± 
2.57* 
13.14 ± 2.12* 993 ± 14.28* 
F7 1:2 1500 48.25 ± 
2.21* 
21.23 ± 3.31* 803 ± 
11.16** 




                                    
Figure 1: Transmission electron micrograph 
(TEM) of NP with 1:2 drug: polymer ratio 
 
Figure 2: DSC of pure GB (A), PLGA (B), 
formulation F2 (drug polymer ratio 1:2)  (C) 
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Figure 3: In vitro release of GB from formulation  
 
Table 2: Release kinetics of GB-loaded NPs 
 






F1 0.9818 0.9422 0.9413 
F2 0.9812 0.9462 0.9326 
F3 0.9726 0.9532 0.9524 




As the polymer content of the NPs increased, 
there was a corresponding increase in 
entrapment efficiency and particle size. This 
may be due to the fact that the higher the 
polymer content the thicker is the coat around 
the drug, which prevents the loss of drug 
during the processing of NPs. The increase in 
particle size with increase in polymer 
concentration may be due to increased 
viscosity of polymeric phase, which resulted 
in the formation of large emulsion droplets 
during homogenization and thus was hard to 
break; hence, they precipitated leading to 
increase in their particle size.  
 
DSC is a fast and reliable method for 
understanding polymorphic transitions when 
screening drugs and excipients for 
compatibility, obtaining information about 
possible interactions. The absence of 
detectable crystalline domains of GB in drug-
loaded NPs clearly indicates that GB was 
dispersed completely in the formulation, thus 
modifying the NPs to an amorphous, 
disordered-crystalline phase.  
 
With increase in polymer concentration, drug 
release decreased due to the fact that 
increase in the polymer amount resulted in 
increase of matrix thickness of NPs, thereby 
increasing the distance that the drug 
transversed to reach the surface of the NPs. 
As drug concentration in the drug/polymer 
mixture in the NPs increased, i.e., from 1:1 to 
2:1, drug release increased. This is because 
the amount of polymer required to coat the 
higher concentration of drug was not 
sufficient to retard drug release.   
 
Overall, formulation F2 which has suitable 
particle size, drug entrapment efficiency and 
controlled release profile was the most 




GB-loaded PLGA NPs were successfully 
prepared by emulsification/solvent evapo-
ration method using varying GB/PLGA ratios. 
Encapsulation efficiency and drug content 
were adequate. Furthermore, drug release 
from the NPs was controlled indicating its 
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